Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2018-12-04
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03357172
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
NCT04935684
The Association of Microbiota Composition With cGVHD After Allo-HSCT
NCT05355675
Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease
NCT03214289
Study of Drug Acceptance and Its Persistence Over Time in Patients Receiving a Haematopoietic Stem Cell Allograft
NCT05164835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient
For all patients included in the study, the following interventions will be performed :
* several blood samples (quantity collected requiring classification of this study as interventional according to French law)
* several fecal samples
* anxiety tests
* stress tests
blood samples
20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
fecal samples
1 g of feces (D-8, D0, D15, D30, D90)
Anxiety test
Test of Spielberger
Stress test
Test of Cohen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood samples
20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
fecal samples
1 g of feces (D-8, D0, D15, D30, D90)
Anxiety test
Test of Spielberger
Stress test
Test of Cohen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients followed at the hospital of Nancy for a allogeneic hematopoietic cell transplantation (HLA matched donor)
* Graft of peripheral blood stem cell
* GVHD prophylaxis by ciclosporin and antilymphocyte serum +/- mycophenolate mofetil or methotrexate.
Exclusion Criteria
* Patients with active HBV or HCV
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RUBIO Marie-Thérèse
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marie-Thérèse RUBIO, PU-PH
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A00676-49
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.